This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013
Findings from available evidence showed a reduction in ADHD symptoms from baseline values for patients receiving either venlafaxine or placebo but the difference between the two groups was not statistically significant, despite a larger number of patients on venlafaxine who met treatment response criteria. The efficacy of modafinil in reducing ADHD symptoms is not significantly different than d-amphetamine, and the superiority of modafinil over placebo is not consistent across trials. There was no evidence on the clinical effectiveness of TCAs and clonidine in the treatment of adults with ADHD. Limited and short-term evidence caution the interpretation of the findings. Randomized controlled studies with extended follow-up periods are needed to confirm the lasting beneficial effects of non-stimulants in the long term and to guide treatment decisions.
Subject indexing assigned by CRD
Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Clonidines; Cyclohexanols; Serotonin Uptake Inhibitors; Wakefulness-Promoting Agents
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published